English | 繁體

Search in the results

UM

Browse/Search Results:  1-4 of 4 Help

Selected(0)Clear Items/Page:    Sort:
β-Elemene enhances erlotinib sensitivity through induction of ferroptosis by upregulating lncRNA H19 in EGFR-mutant non-small cell lung cancer Journal article
Xu Cong, Jiang ZeBo, Shao Le, Zhao ZiMing, Fan XingXing, Sui XinBing, Yu LiLi, Wang XuanRun, Zhang RuoNan, Wang WenJun, Xie YaJia, Zhang YiZhong, Nie XiaoWen, Xie Chun, Huang JuMin, Wang Jing, Wang Jue, Leung Elaine Lai Han, Wu QiBiao. β-Elemene enhances erlotinib sensitivity through induction of ferroptosis by upregulating lncRNA H19 in EGFR-mutant non-small cell lung cancer[J]. Pharmacological Research, 2023, 191, 106739.
Authors:  Xu Cong;  Jiang ZeBo;  Shao Le;  Zhao ZiMing;  Fan XingXing; et al.
Favorite | TC[WOS]:31 TC[Scopus]:28  IF:9.1/9.0 | Submit date：2023/06/05
Erlotinib  Ferroptosis  Lncrna H19  Nsclc  Β-elemene  
Tumor vasculature normalization by orally fed erlotinib to modulate the tumor microenvironment for enhanced cancer nanomedicine and immunotherapy Journal article
Chen, Qian, Xu, Ligeng, Chen, Jiawen, Yang, Zhijuan, Liang, Chao, Yang, Yu, Liu, Zhuang. Tumor vasculature normalization by orally fed erlotinib to modulate the tumor microenvironment for enhanced cancer nanomedicine and immunotherapy[J]. BIOMATERIALS, 2017, 148, 69-80.
Authors:  Chen, Qian;  Xu, Ligeng;  Chen, Jiawen;  Yang, Zhijuan;  Liang, Chao; et al.
Favorite | TC[WOS]:87 TC[Scopus]:92  IF:12.8/13.1 | Submit date：2018/10/30
Erlotinib  Vascular Normalization  Tumor Microenvironment  Nanomedicine  Immunotherapy  
Anti-cancer synergy of dichloroacetate and EGFR tyrosine kinase inhibitors in NSCLC cell lines Journal article
Yang,Zheng, Tam,Kin Y.. Anti-cancer synergy of dichloroacetate and EGFR tyrosine kinase inhibitors in NSCLC cell lines[J]. European Journal of Pharmacology, 2016, 789, 458-467.
Authors:  Yang,Zheng;  Tam,Kin Y.
Favorite | TC[WOS]:31 TC[Scopus]:31  IF:4.2/4.3 | Submit date：2021/03/04
Dichloroacetate  Drug Combination  Epidermal Growth Factor Receptor  Erlotinib  Gefitinib  Pyruvate Dehydrogenase Kinase  
Anti-cancer synergy of dichloroacetate and EGFR tyrosine kinase inhibitors in NSCLC cell lines Journal article
Yang Z., Tam K.Y.. Anti-cancer synergy of dichloroacetate and EGFR tyrosine kinase inhibitors in NSCLC cell lines[J]. European Journal of Pharmacology, 2016, 789, 458-467.
Authors:  Yang Z.;  Tam K.Y.
Favorite | TC[WOS]:31 TC[Scopus]:31 | Submit date：2018/12/18
Dichloroacetate  Drug Combination  Epidermal Growth Factor Receptor  Erlotinib  Gefitinib  Pyruvate Dehydrogenase Kinase